Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS VIVUS Inc. daily Stock Chart
VVUS [NASD]
VIVUS Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own0.30% Shs Outstand103.81M Perf Week-7.23%
Market Cap239.80M Forward P/E- EPS next Y-0.61 Insider Trans481.07% Shs Float97.72M Perf Month-8.33%
Income-82.60M PEG- EPS next Q-0.23 Inst Own66.40% Short Float36.52% Perf Quarter-4.94%
Sales109.70M P/S2.19 EPS this Y53.80% Inst Trans-4.98% Short Ratio35.07 Perf Half Y-19.79%
Book/sh0.66 P/B3.50 EPS next Y27.40% ROA-21.80% Target Price4.50 Perf Year-56.58%
Cash/sh2.77 P/C0.83 EPS next 5Y0.80% ROE-87.80% 52W Range2.22 - 5.45 Perf YTD-19.79%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-16.10% 52W High-57.61% Beta1.46
Dividend %- Quick Ratio5.20 Sales past 5Y29.50% Gross Margin69.20% 52W Low4.05% ATR0.10
Employees94 Current Ratio5.80 Sales Q/Q-12.30% Oper. Margin-41.50% RSI (14)40.24 Volatility4.55% 4.06%
OptionableYes Debt/Eq3.37 EPS Q/Q0.00% Profit Margin-75.20% Rel Volume0.65 Prev Close2.32
ShortableYes LT Debt/Eq3.17 EarningsAug 04 AMC Payout- Avg Volume1.02M Price2.31
Recom2.80 SMA20-6.14% SMA50-6.24% SMA200-20.36% Volume660,346 Change-0.43%
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Oct-29-10Reiterated JMP Securities Mkt Outperform $12 → $16
Aug-03-10Downgrade Brean Murray Hold → Sell $2
Jul-16-10Reiterated Wedbush Outperform $20 → $10
Jun-24-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
May-29-15 11:22AM  Vivus gets a vote of confidence
May-27-15 02:30PM  Zogenix says former obesity drug reduced seizures in study
May-14-15 07:00AM  VIVUS Announces Scientific Presentations Marketwired
May-13-15 01:04PM  VIVUS INC Financials
May-08-15 08:09PM  10-Q for VIVUS, Inc. at Company Spotlight
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
May-06-15 04:19PM  VIVUS INC Files SEC form 10-Q, Quarterly Report
10:59AM  VIVUS Q1 Loss Narrower-than-Expected, Revenues Beat - Analyst Blog
May-05-15 06:34PM  VIVUS Reports First Quarter 2015 Financial Results at noodls
04:45PM  Vivus reports 1Q loss
04:30PM  VIVUS Inc Earnings Call scheduled for 4:30 pm ET today
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  VIVUS Reports First Quarter 2015 Financial Results Marketwired
07:07AM  Q1 2015 VIVUS Inc Earnings Release - After Market Close
Apr-30-15 07:22AM  VIVUS Announces Date of First Quarter 2015 Update and Financial Results Conference Call at noodls
07:00AM  VIVUS Announces Date of First Quarter 2015 Update and Financial Results Conference Call GlobeNewswire
Apr-28-15 04:04PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
07:00AM  VIVUS Announces New Discount Program Through Sam's Club for Qsymia Patients Marketwired
Apr-21-15 05:00PM  VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia at noodls
04:37PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:30PM  VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia Marketwired
Apr-17-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-16-15 06:16PM  VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog
06:03AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-15-15 08:19PM  VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents at noodls
07:30PM  VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents Marketwired
Apr-14-15 07:06AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Apr-10-15 08:40AM  PharmalotPharmalittleGood Morning: We're Catching up on Eisai, HepC Research, Pfizer and Ebola at The Wall Street Journal
07:11AM  VIVUS to Present at Upcoming Investor Conference at noodls
07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
02:00AM  Eisai Drops On US Job Cuts, Still A Stunning Run On Alzheimer's Drug With Biogen at Barrons.com
Apr-09-15 06:24PM  Japanese Drug Company Eisai to Cut 25% of U.S. Jobs at The Wall Street Journal
Apr-02-15 02:40PM  Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? at The Wall Street Journal
Mar-30-15 04:31PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:19PM  VIVUS Announces Operational Update at noodls
04:05PM  VIVUS Announces Operational Update Marketwired
Mar-27-15 10:06PM  A Look at Pharma Company Dermira's Performance
08:25AM  Ahead of the Bell: Orexigen shares rise
06:50AM  The young & the restless: 6 who are hot at CNBC
Mar-20-15 05:29PM  Ferrellgas, Prothena Lead Friday's After-Hours Movers
Mar-10-15 01:51PM  4 Stocks Under $10 Making Big Moves Higher at TheStreet
07:06AM  VIVUS INC Files SEC form 8-K, Other Events
Mar-09-15 07:58AM  Early movers: GM, RTI, AMZN, AAPL, BBRY & more at CNBC
07:06AM  VIVUS INC Files SEC form 8-K, Other Events
Mar-06-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-03-15 03:36PM  Nasdaq backs off from 5,000
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
Feb-27-15 07:08PM  10-K for VIVUS, Inc. at Company Spotlight
Feb-26-15 11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog +5.91%
Feb-25-15 04:13PM  VIVUS INC Files SEC form 10-K, Annual Report EDGAR Online -8.96%
12:41PM  JPM Securities Picks Through Biotech News For Winners
09:40AM  VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog
Feb-24-15 05:12PM  Vivus reports 4Q loss AP
04:30PM  VIVUS Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q4 2014 Vivus Inc Earnings Release - After Market Close CCBN
Feb-20-15 03:47PM  Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus at TheStreet +7.46%
11:24AM  Activists want 'imminent retirement' of Ariad CEO at CNBC
07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
Feb-19-15 07:00AM  VIVUS Announces Date of Fourth Quarter and Year End 2014 Update and Financial Results Conference Call GlobeNewswire
Jan-29-15 07:09AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity Marketwired
Jan-27-15 04:06PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-26-15 04:06PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-23-15 06:25AM  Coverage initiated on Vivus by RBC Capital Mkts Briefing.com +6.20%
Jan-22-15 04:04PM  The 52-Week Low Club for Thursday at 24/7 Wall St. -5.15%
04:00PM  Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Zacks
Jan-15-15 07:01AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -7.33%
Jan-14-15 05:25PM  Obesity Device That Makes You Feel Full to Cost $15,000 at Bloomberg
01:55PM  5 Obesity Stocks Investors Are Watching Benzinga
Jan-13-15 04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online -6.36%
Jan-09-15 07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
Dec-23-14 04:49PM  FDA clears Novo Nordisk's weight loss drug Saxenda AP
Dec-19-14 02:09PM  Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Benzinga
08:25AM  Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators at TheStreet
Dec-17-14 07:42AM  Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Yahoo Finance Contributors
Dec-15-14 07:00AM  VIVUS Announces Favorable Formulary Positioning for Qsymia Marketwired
Dec-12-14 11:58AM  Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Yahoo Finance Contributors
Dec-09-14 05:34AM  Others Overlooked VIVUS (VVUS), Should You Buy It Now? Zacks
Dec-02-14 03:00AM  Europe shares open higher; oil price watched CNBC
Dec-01-14 06:25PM  Cramer: State of holiday retail CNBC -5.67%
Nov-26-14 07:06AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia Marketwired
Nov-19-14 05:48AM  Why VIVUS (VVUS) Might Be a Diamond in the Rough Zacks
Nov-13-14 12:10PM  What's Driving Orexigen Therapeutics Higher? Benzinga
Nov-12-14 04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
Nov-10-14 11:02AM  Orexigen rises as weight loss drug review proceeds AP
Nov-07-14 07:08PM  10-Q for VIVUS, Inc. Company Spotlight
Nov-06-14 03:45PM  VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up Zacks
Nov-05-14 05:45PM  Vivus tops Street 3Q forecasts AP
04:30PM  Vivus Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:06PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:00PM  VIVUS Reports Third Quarter 2014 Financial Results Marketwired
07:07AM  Q3 2014 Vivus Inc Earnings Release - After Market Close CCBN
Nov-03-14 07:00AM  VIVUS Announces Qsymia Presentations at Obesity Week 2014 Marketwired
Oct-30-14 07:00AM  VIVUS Announces Date of Third Quarter 2014 Update and Financial Results Conference Call GlobeNewswire
Oct-20-14 01:10PM  Notable option trades in equities optionMONSTER
Oct-09-14 07:00PM  Endo Buyout Of Auxilium Joins Two Changing Firms at Investor's Business Daily
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Day WesleyVP, Clinical DevelopmentJan 29Sale2.784721,31256,999Jan 30 04:15 PM
Sanford Svai SCFO & Chief Accounting OfficerJan 29Sale2.784721,31265,559Jan 30 04:14 PM
MARSH GUY PVP, US Operations & GMJan 29Sale2.7823866231,487Jan 30 04:14 PM
Slebir John LSVP, Business Development & GCJan 29Sale2.786301,75172,799Jan 30 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 08Buy3.22217,900701,64012,500,000Jan 09 04:37 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 07Buy3.05282,100859,70112,282,100Jan 09 04:37 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 06Buy3.03147,936448,79812,000,000Jan 07 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 05Buy3.05328,8641,002,37111,852,064Jan 07 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 02Buy2.99218,400652,84511,523,200Jan 05 04:21 PM
NORTH TIDE CAPITAL, LLC10% OwnerDec 31Buy2.83304,800862,68011,304,800Jan 05 04:21 PM